1 |
KATSURA C, OGUNMWONYI I, KANKAM H K, et al.Breast cancer:presentation, investigation and management [J].Br J Hosp Med (Lond),2022,83(2):1-7.
|
2 |
艾勇彪,黄军,袁杰,等. 早期三阴性乳腺癌中雄激素受体表达与临床病理特征及预后的关系[J]. 实用医学杂志,2023,39(8):975-979.
|
3 |
MOHAJAN S, JAISWAL P K, VATANMAKARIAN M,et al.Hippo pathway:Regulation,deregulation and potential therapeutic targets in cancer[J]. Cancer Lett,2021,507:112-123. 112-123.
|
4 |
YU B, SU J, SHI Q, et al.KMT5A-methylated SNIP1 promotes triple-Negative brea -st cancer metastasis by activating YAP signaling[J].Nat Commun,2022,13(1):2192.
|
5 |
THOMPSON B J.YAP/TAZ:Drivers of Tumor Growth,Metastasis, and Resistance to Therapy[J].Bioessays,2020,42(5):e1900162.
|
6 |
XU T, JIANG Y Y, YUAN S Y, et al.Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-ɑAxis[J]. Front Oncol,2022,12:899402.
|
7 |
WANG X R, JIANG Z B, XU C, et al.Andrographolide suppresses non-small-non Lung cancer progression through induction of autophagy and antitumor immune response[J]. Pharmacol Res, 2022,179:106198.
|
8 |
LIU Z Y, WU X P, DAI K, et al. The new andrographolide derivative AGS-30 induces apoptosis in human colon cancer cells by activating a ROS-dependent JNK signalling pathway[J]. Phytomedicine,2022,94:153824.
|
9 |
HE J, CHEN Z, XUE Q, et al.Block of Proliferation 1 Promotes Proliferation, Invasion and Epithelial Mesenchymal Transformation in Gastric Cancer[J]. Oxid Med Cell Longev,2022,2022:2946989.
|
10 |
鹿蓓蓓,傅鹤秀, OKRAH E A,等,穿心莲内酯对小鼠乳腺癌的抑制作用和机制 [J]. 中国药理学通报,2022,38(1):26-32.
|
11 |
Fu M, Hu Y, Lan T, et al.The Hippo signalling pathway and its implications in human health and diseases[J]. Signal Transduct Target Ther,2022, 7(1):376.
|
12 |
MOHAJAN S, JAISWAL P K, VATANMAKARIAN M,et al.Hippo pathway:Regulation, deregulation and potential theraeutic targets in cancer[J]. Cancer Lett,2021,507:112-123.
|
13 |
MA S, MENG Z, CHEN R, et al.The Hippo Pathway: Biology and Pathophysiology [J]. Annu Rev Biochem,2019,88:577-604.
|
14 |
CUNNINGHAM R, HANSEN C G. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer[J].Clin Sci (Lond),2022,136(3):197-222.
|
15 |
KUO C Y, CHANG Y C, CHIEN M N, et al. SREBP1 promotes invasive phenotyp- es by upregulating CYR61/CTGF via the Hippo-YAP pathway[J]. Endocr Relat cancer,2021,29(2):47-58.
|
16 |
PAN X X, GENG Z, LI J Y, et al. Peptide PDHPS1 Inhibits Ovarian Cancer Growth through Disrupting YAP Signaling [J].Mol Cancer Ther,2022,21(7):1160-1170.
|
17 |
MOYA I M, HALDER G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine[J]. Nat Rev Mol Cell Biol, 2019,20(4):211-226.
|
18 |
SUN T, MAO W H, PENG H,et al.YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin[J].Cell Oncol (Dordr),2021,44(3): 689-699.
|
19 |
LUO J, ZOU H, GUO Y, et al. The oncogenic roles and clinical implications of YAP/TAZin breast cancer[J]. Br J Cancer,2023,128(9):1611-1624.
|
20 |
YANG C E, LEE W Y, CHENG H W, et al.The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells[J]. Chem Biol Interact, 2019,302: 28-35.
|
21 |
徐钰,徐婷,熊远锋,等. 二甲双胍可能通过 Hippo-YAP通路抑制HER-2阳性乳腺癌细胞的增殖和促进凋亡[J].南方医科大学学报,2022,42(5):740-746.
|
22 |
LUO Y W, ZHOU J, TANG J N, et al. MINDY1 promotes bladder cancer progressi- on by stabilizing YAP[J]. Cancer Cell Int, 2021,21(1):395.
|
23 |
TANG J N, LUO Y W, XIAO L. USP26 promotes anaplastic thyroid cancer progre- ssion by stabilizing TAZ[J]. Cell Death Dis, 2022,13(4):326.
|
24 |
WANG L J, LI J, WANG R L,et al.NGF signaling interacts with the Hippo/YAP pathway to regulate cervical cancer progression[J]. Front Oncol,2021,11:688794.
|
25 |
朱德明,孔连宝,贾文博,等. ANKRD1通过介导上皮细胞间充质转化促进肝细胞肝癌增殖与转移[J]. 南京医科大学学报,2023,43(4):484-491.
|